×

Nymox Announces Completion of Patient Enrollment in Pivotal U.S. Phase 3 BPH Study

HASBROUCK HEIGHTS, N.J., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today completion of patient enrollment in the Company's pivotal U.S. Phase 3 NX02-0017 Study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3 Study are expected in late 2013.

Paul Averback MD, CEO of Nymox said, "Our drug development programs for NX-1207 include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, and other clinical and non-clinical research activities. Over 2000 patients have participated to date in NX-1207 trials. Final completion of enrollment in this major pivotal study is an important milestone in the NX-1207 development pathway. We look forward to further milestones as this and other trials are completed and results are reported."

NX-1207 is in late stage Phase 3 development in the U.S. for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth in prostate size as men age. The Company's NX02-0018 Phase 3 trial is expected to reach full enrollment in the near future. Phase 3 trial activities of NX-1207 for BPH have begun in Europe sponsored by Recordati S.p.A., the company's European licensing partner. In the BPH studies to date, a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs.

NX-1207 is also being evaluated for the treatment of low risk localized prostate cancer where NX-1207 is administered directly into the area of the prostate where the cancer was detected. A U.S. Phase 2 study (NX03-0040) for that indication is in progress.

BPH causes progressive difficulties with urination, such as nocturia, urge to void frequently, acute urinary retention and other problems. The condition can seriously impact the health and quality of life of middle aged and older men. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and a high proportion of men as they age suffer from moderate to severe urinary problems and symptoms associated with BPH.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT: For Further Information Contact: Roy Wolvin Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.comSource:Nymox Pharmaceutical Corporation